anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a multi-institution, open label phase II study designed to investigate the feasibility of gemcitabine/cisplatin/nab-paclitaxel as a neoadjuvant systemic chemotherapy for patients with reseactable oncologically high-risk IHCCA. This study will enroll up to 34 patients from all participating institutions with an accrual rate of 2 patients per month.

This will be an open-label, single arm study with each cycle equal to 21 days. All three drugs will be administered intravenously on day 1 and day 8 of each cycle. Dosing will be calculated using body surface area (BSA) based on the actual weight of the patient at each visit. Nab-Paclitaxel will be given at 100 mg/m2, followed by cisplatin at 25 mg/m2 and then gemcitabine at 800 mg/m2 for 2 weeks in a row followed by a week of rest. Patients will receive 4 cycles of neoadjuvant systemic chemotherapy. Restaging will be done after every 2 cycles (+/- 1 week) by radiological imaging. If radiological scans demonstrate stable disease or partial or complete tumor response and the tumor remains resectable, surgery will be performed. For patients with radiological scans that document disease progression during the study, treatment will be discontinued off the protocol and will not be evaluable for other secondary endpoints. Resection will be performed per standard of care and will include a portal lymphadenectomy for all cases. Objective evidence of recurrent disease after resection will be recorded at the time of recurrence. Patients will be followed for overall survival endpoint as well.
PROBLEM TO BE SOLVED: To obtain an oral cavity composition having an excellent alveolar bone absorption-inhibiting effect, safe even when used in an oral cavity for a long time, and useful for preventing and treating periodontal diseases by adding a Coleus forskohlii root extract as an active ingredient. SOLUTION: This composition for oral cavities contains a Coleus forskohlii root extract as an active ingredient. A solvent used for obtaining the plant extract preferably is methanol, ethanol, water, etc. The extraction treatment is carried out at a temperature of 3-70 deg.C. The Coleus forskohlii root extract is preferably compounded in an amount of 0.000001-1 wt.% as a concentrated extract on the basis of the total amount of the composition. The composition may further be compounded with a nonionic surfactant (for example, polyoxyethylene hydrogenated castor oil), a viscous agent (for example, sorbitol), etc., in the cases of a gargle, a mouth wash, etc. The composition may further be compounded with a silica-based abrasive (for example, precipitated silica), a synthetic binder (for example, polyvinyl-pyrrolidone), etc., in the case of a dentifrice.
PURPOSE:To obtain an oligopeptide fraction having a predetermined mol.wt. and usable for a desired purpose such as a foaming agent by successively treating an enzyme decomposition product of ungula/horns using a UF membrane and an RO membrane and to recycle RO membrane transmitted matter to enzyme reaction to use the same. CONSTITUTION:An enzyme decomposition product can be treated in a closed system generating no environmental pollution. The enzyme decomposition product is successively treated using a UF membrane and an RO membrane to obtain an oligopeptide fraction devided into desired molecular fractions. This fraction can be used as a foaming compsn. or a cosmetics material. Since Fe<2+> is used in the production of the foaming compsn., the foaming compsn. excellent in foamability and the holding power of an air bubble is obtained. The oligopeptide compsn. with a low mol.wt. transmitted through the RO membrane has a light color and can be used as a cosmetics material as it is. RO membrane transmitted matter is recycled to enzyme reaction to be reutilized and the enzyme decomposition product is effectively treated without bringing about environmental pollution.
In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
Breastfeeding is the optimal feeding during early childhood. However, the prevalence of exclusive breastfeeding is not as expected. The evidence of effectiveness of interventions designed to support breastfeeding is not conclusive. Breastfeeding is a complex experience, influenced by numerous factors, as self-efficacy, that require interdisciplinary approaches.The aim of the study is to design and pilot the effect of a complex intervention to support mothers' breastfeeding self-efficacy and professional self-efficacy to support breastfeeding families, considering breastfeeding as a health promoting behavior. The project will be done in two stages a) design of the intervention and b) experimental pilot trial with control and intervention groups, for evaluation of feasibility, acceptability of the intervention and preliminary estimate of its effect on maternal and professional self-efficacy. The project will be carry out in two public outpatient clinics (Centro de Salud Familiar Alberto Hurtado y Centro de Salud Familiar Juan Pablo II) in Santiago, Chile. Participants will be breastfeeding women and their partner/family member; and health professionals who provide care to mother and child. Intervention group will receive a breastfeeding workshop during the third trimester of pregnancy and on-line breastfeeding support during the first 6 months postpartum. Health professionals will be train to deliver the intervention.Control group will receive the standard care as provided in the outpatient clinic.
Methods and apparatus are described for synthesizing and distributing personal care products in a retail environment. Preference data are generated in the retail environment. The preference data are representative of expressed preferences of a consumer with regard to personal care. In response to the preference data, instructions for reproducibly synthesizing at least one personal care product are generated in a format perceivable and understandable by humans. The at least one personal care product is synthesized in the retail environment in accordance with the instructions. The at least one personal care product is provided to the consumer before the consumer leaves the retail environment.
Genetic counselors may be faced with situations in which they disagree on a moral level with the views or decisions of their clients. These moral value conflicts between counselors and their clients may have negative emotional consequences for counselors. Little is known about the range of sources of these conflicts, the approaches counselors take to address them, or the impact they have on the counselor's life and career. This study seeks to gain insight into the nature, sources, and consequences of moral value conflicts among genetic counselors through semi-structured in-depth interviews with approximately 30 genetic counselors. Interview questions will be nested within interviews for a larger study entitled "Moral Distress and Suffering of Genetics Professionals". The discussion will be centered on a personal experience of moral value conflict that the counselor has had with a client. Interviews will be transcribed and subjected to thematic analysis. Such analysis will result in the identification of common themes running through the interviews. An understanding of value conflicts may allow for future interventions to minimize the negative effects of these events.
This is an open label, 2 visit, pilot study of 25 subjects with a diagnosis of episodic migraine with or without aura according to the International Classification of Headache Disorders (2nd Edition-2004).

Subjects will be screened at Visit 1 after being properly consented for participation in the study. Screening procedures will include assessment of the medical history, headache history, current medications, vital signs, height and weight measurements and a urine pregnancy test for women of childbearing potential. Investigators will determine the eligibility of study subjects. Subjects will be instructed on how and when to apply the topical gel to treat a migraine attack. In addition, subjects will be instructed how to complete the take home diary. The study medication will be used at home to treat a single migraine attack.

At the time of at-home treatment the subject will apply the study medication. The gel will be applied to the area below and abutting the back base of the skull to base of neck and span from behind and between both ears. The quantity shall be two pumps from the metered dosing bottle. The best way to apply is to pump once onto the fingertips and apply the gel to one-half of the application area and pump again onto the fingertips and apply the gel to the other half of the application area. Massage in for 5 to 10 seconds to make sure there is reasonably uniform coverage. (Do not cover with cloth or bandage or lie down on a pillow until the gel has completely dried - about 10 minutes or so.) Do not get any of the gel into the eyes or onto mucus membranes. The gel is not toxic but will cause a burning sensation to eyes or mucus membranes. Wash hands with soap and warm water after application. The gel will give rise to a cooling sensation and to it may feel like a mild to moderate stinging or burning sensation. That is normal. Anything more than a mild to moderate stinging or burning sensation is not expected and should be noted in diary. If there has been no reduction in symptoms after 30 minutes repeat the application. If there is no relief after 2 hours the subject may use other rescue medication.

Completed subject diaries will provide data on headache severity and the presence or absence of nausea, vomiting, photophobia and phonophobia. Time of resolution of both the headache and accompanying symptoms will be collected. The subjects will record migraine pain severity and the presence or absence of associated symptoms at 30, 60, 90 minutes and 2, 4, and 24 hours after the administration of study drug.

Subjects will be asked to treat a single migraine attack within 8 weeks of Visit 1. After treating the attack and completing the diary, they will be asked to return to Jefferson Headache Center for a final visit (Visit 2) or to return the diary and other study supplies by mail. Shipping materials will be provided to each participant.
Define the phenotypic characteristics, severity and clinical evolution of FD on a patient-by patient basis. Investigators will enroll patients with FD in a multi-center observational natural history study to evaluate their biochemical, neurological and autonomic phenotype. Investigators will follow patients to systematically study the onset and scaled severity of all clinical problems. Investigators will define progression rates of patients outside of a clinical trial to distinguish between static and progressive features, a challenge in congenital neuropathies. Investigators will continue banking blood to look for ways to monitor the disease phenotypes. Biomarkers that quantify renal, cardiovascular, respiratory, skeletal and cognitive aspects of the disease will be evaluated. This information is relevant when monitoring toxicity to drugs in clinical trials. Detailed clinical follow-up of patients with FD will allow investigators to determine when standard of care therapies (e.g., non-invasive ventilation, gastrostomy feedings) should be initiated and how these impact survival outcomes.

Specific Aim 2: Develop ways to measure progressive neurological deficits as outcome measures for future clinical trials. Investigators will test the hypothesis that worsening gait ataxia and progressive visual loss are caused by ongoing neuronal degeneration. Investigators will develop precise outcome measures based on these deficits to test the efficacy of new treatments. Investigators will prospectively evaluate longitudinal changes in the retinal structure (with optical coherence tomography) and visual function in a cohort of patients with FD. Investigators will determine the extent and severity of retinal abnormalities in all patients and how they change overtime. Investigators will establish whether structural abnormalities in the retina are correlated with disease severity and look for functional correlates as measured by visual acuity and color discrimination. Following the recent discovery that gait ataxia in patients with FD is the result of sensory deficits, investigators will perform quantitative assessments of passive joint angle matching at the knee to measure proprioceptive acuity. Investigators will determine how these measures change overtime as well as their impact on daily function and quality of life.

An organized, multi-site natural history study of patients with FD will enable investigators to define disease-specific outcomes for testing new therapies, a major breakthrough for these patients. The study also offers a unique opportunity to understand better how the brain develops when devoid of crucial sensory inputs.
A depressive state with classical symptoms such as low (depressive/sad) mood, markedly diminished interest in activities, significant weight loss/gain, insomnia or hypersomnia, psychomotor agitation/retardation, excessive fatigue, inappropriate guilt, diminished concentration, and recurrent thoughts of death, persisting for more than 2 weeks is classified as major depressive disorder (MDD). The mechanism of action of ketamine is distinct from conventional antidepressants (ADs), which target the monoamines (serotonin, norepinephrine, and/or dopamine). Esketamine, the S-enantiomer of ketamine, is approved and widely used for the induction and maintenance of anesthesia via intramuscular or intravenous (IV) administration. There is a significant unmet need to develop novel AD treatments based on the relevant psychophysiological pathways underlying MDD. The goal of any novel treatment would be the rapid and long-lasting relief of depressive symptoms, especially in participants with treatment-resistant depression (TRD), who lack a sufficient response to the currently available treatment strategies. The study consists of a Screening Phase (up to 14 days), an Acute Phase (8 Weeks), a Maintenance Phase (24 Weeks) and a Safety Follow-up Phase (2 Weeks). Safety assessment includes adverse event, serious adverse events, physical examination, vital signs, electrocardiogram, clinical safety laboratory assessments, suicidal risk monitoring. The total duration of the study is approximately 36 Weeks for all participants.
INTRODUCTION: Fibrosis is a typical pathological characteristic in IgG4-RD patients and often irreversible. There exists a lack of suitable markers for detection of earlier onset of fibrosis in various organs in IgG4-RD patients. Hence, this study aims at analysing ambispectively the myofibroblasts and the pro-fibrotic cytokines, IFN gamma and IL-33 involved in IgG4-RD associated fibrosis in South Asian patients.
METHOD: Archived biopsy samples of definite/probable/possible cases of IgG4-RD, classified according to diagnostic criteria, taken from patients who attended the OPD and IPD of our tertiary care centre during January 2015-January 2020 were chosen for this study. The paraffin sections were examined qualitatively for fibrosis and the excessive collagen deposition by Hematoxylin & Eosin and Masson's Trichrome staining. Also, the presence of alpha-Smooth muscle actin (α-SMA) expressing myofibroblasts and the involvement of pro-fibrotic cytokines (IFN-gamma, IL-33) were assessed by Immunohistochemistry and scored semi-quantitatively (+mild, ++moderate, +++ severe). Serum IL-33 levels were analysed by indirect Elisa (R & D Systems).
RESULTS: Myofibroblasts were present in 10/12 biopsy samples, in moderate levels in 4 (33%) and very high levels (+++) in 3 (25%) of the patients. IFN-gamma was expressed at low levels in 6 (50%) and absent in 6 (50%). All patients showed IL-33 expression with very high levels in tissue (6, 50%), as well as in serum samples.
CONCLUSION: The findings of this study reinforce the role of myofibroblasts and profibrotic cytokines like IL-33 in fibrosis of Ig4-RD patients, pointing to their potential as earlier predictive markers of onset and extent of fibrosis.
The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
Spinal Cord Injury (SCI) is a severe condition that often leads to substantial neurological impairments. This study aimed to explore the role of Aquaporin-4 (AQP4) in regulating astrocyte autophagy and neuroinflammation post-SCI, as well as to evaluate the therapeutic potential of AQP4 inhibition using the specific inhibitor TGN-020. Using Western blot, CCK8 assays, immunofluorescence staining, histopathological assessments, and behavioral analyses, we investigated the effects of TGN-020 on SCI-induced alterations in autophagy, neuroinflammation, astrocyte proliferation, neuronal damage, and motor function recovery in both rat and astrocyte models. Our findings indicate that TGN-020 significantly enhances astrocyte autophagy, reduces neuroinflammation, thereby leading to mitigated astrocyte activation by suppressing AQP4 expression. These beneficial effects are associated with the activation of the peroxisome proliferator-activated receptor-γ/mammalian target of rapamycin (PPAR-γ/mTOR) signaling pathway. Notably, the introduction of the PPAR-γ specific inhibitor GW9662 abrogated the positive regulatory effects of TGN-020 on SCI-induced autophagy and neuroinflammation. Collectively, our in vivo and in vitro experiments demonstrate that TGN-020, by down-regulating AQP4, activates the PPAR-γ/mTOR pathway, ameliorates astrocyte autophagy, diminishes neuroinflammation, and ultimately enhances motor function recovery.
PURPOSE:To provide the subject new compound having excellent anti- thrombogenic activity, usable in either of oral and parenteral administration routes, useful as antithrombotic agent. CONSTITUTION:The objective 2,5-pyrrolidinedione derivative of formula I (ring A is tri-lower alkoxyphenyl) or a pharmacologically permissible salt thereof, e.g. 3-[(E)-benzylidene]-4-[(Z)-3,4,5-trimethoxybenzylidene]-2,5-pyrrolidin edione. The compound of the formula I can be obtained by intramolecular ring closure of a carbamoyl compound of formula II (R<1> and R<2> are such that one of them lower alkoxy and the other is amino) followed by, if desired, making the product into a pharmacologically permissible salt. This compound, serving as an antithrombotic agent, is useful as a preventive or therapeutic agent for e.g. angiopathy such as cardiac infarction, cerebral apoploxy, or pulmonary embolism and diabetic complications, being also usable as a preventive agent for the reobstruction after percutaneous coronary plastic operations or thrombolytic therapies.
The invention relates to the field of treatment of drug-resistant tumors, in particular to application of a small molecular compound in preparation of a medicine for treating regorafenib-resistant liver cancer. The invention discloses that an SphK2 inhibitor OPAGANIB can reverse drug resistance of liver cancer to regorafenib. We find that the OPAGANIB-treated drug-resistant cell strain has obviously improved sensitivity to regorafenib on regorafenib liver cancer drug-resistant cell strains and in-vivo liver cancer drug-resistant models. After over-expressing SphK2, the sensitivity of the drug-resistant cell strain to regorafenib is obviously reduced. The result shows that the inhibition of the activity of SphK2 can effectively improve the sensitivity of the liver cancer cells to regorafenib, so that the problem of drug resistance of liver cancer to regorafenib can be solved. The invention uses OPAGANIB to inhibit the activity of SphK2, thereby achieving the purpose of reversing the drug resistance of liver cancer to regorafenib.
Tolerance mechanisms to single abiotic stress events are being investigated in different plant species, but how plants deal with multiple stress factors occurring simultaneously is still poorly understood. Here, we introduce Salicornia europaea as a species with an extraordinary tolerance level to both flooding and high salt concentrations. Plants exposed to 0.5MNaCl (mimicking sea water concentrations) grew larger than plants not exposed to salt. Adding more salt reduced growth, but concentrations up to 2.5MNaCl were not lethal. Regular tidal flooding with salt water (0.5MNaCl) did not affect growth or chlorophyll fluorescence, whereas continuous flooding stopped growth while plants survived. Quantitative polymerase chain reaction (qPCR) analysis of plants exposed to 1% oxygen in air revealed induction of selected hypoxia responsive genes, but these genes were not induced during tidal flooding, suggesting that S. europaea did not experience hypoxic stress. Indeed, plants were able to transport oxygen into waterlogged soil. Interestingly, sequential exposure to salt and hypoxic air changed the expression of several but not all genes as compared to their expression upon hypoxia only, demonstrating the potential to use S . europaea to investigate signalling-crosstalk between tolerance reactions to multiple environmental perturbations.